Cubist制药公司一项旨在允许特定患者服用该公司生产的抗生素Cidecin（达托霉素）的研究被延长。
基于1个网页-相关网页
For Cubist's Cidecin, sales will be even smaller--only a few hundred million dollars.
FORBES: Antibiotic Breakthroughs Fall Short
Cubist's injectible antibiotic Cidecin targets S. aureus and similarly resistant bugs in hospitals.
FORBES: A Better Antibiotic?
Cubist fixed the problem and sees Cidecin as an important new medicine that could significantly boost the tiny Cambridge, Mass.
应用推荐
模块上移
模块下移
不移动